Treatment With Aspirin After Preeclampsia: TAP Trial
Sponsor: Malamo Countouris • ClinicalTrials.gov ID: NCT06281665
Recruiting for Similar Conditions?
Sponsors are looking for patients like you. See if you qualify for compensated research studies.
Check Eligibility →Description
The objective of this research project is to conduct a single-site pilot trial to assess the feasibility and effect of low-dose aspirin to augment vascular recovery in the immediate postpartum period after preeclampsia through two specific aims: 1) to pilot test the feasibility of conducting a randomized controlled trial of postpartum low dose aspirin vs. placebo, and 2) to assess the effect of postpartum aspirin on endothelial function and blood pressure. Our central hypothesis is that postpartum administration of low-dose aspirin following preeclampsia will be feasible, improve endothelial function, and lower BP at 6 months postpartum. Subjects will undergo 3 study visits involving BP measurements, blood draws, questionnaires, and/or microiontophoresis. Up to 60 adult subjects will be enrolled at Magee-Women's Hospital.
Interventions
-
Low-dose aspirin
(Drug)
The intervention group will receive low-dose \[81 mg\] aspirin pill daily for 6 months.
-
Placebo
(Drug)
The control group will receive similar appearing placebo daily for 6 months.
Eligibility criteria
Conditions
Locations
- University of Pittsburgh Magee-Womens Hospital — Pittsburgh, Pennsylvania, United States
Partner with Nurenyx
Showcase your study to thousands of motivated patients matching your criteria.
Learn MoreOfficial Source
Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
View Official Record